Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc is experiencing robust growth in the ACTH gel market and anticipates further increases in operating margin, projecting an adjusted operating margin growth from 25.4% in 2024 to 29.7% by 2028. The company expects to generate over $630 million in operating cash flow from 2025 to 2028, bolstered by strong revenue performance in recent quarters and positive demand for key products. Additionally, increased prescription volumes for new launches and anticipated positive contributions from legacy brands and generics are driving upward revisions in revenue estimates, supporting a favorable outlook for the company's financial performance.

Bears say

ANI Pharmaceuticals has witnessed a notable decline in revenue within its Brands segment during the second and third quarters of 2024, attributed to changing market conditions for certain molecules and specific pricing pressures faced by its flagship product, Cortrophin. The company's revenue estimates for 1Q 2025 have been adjusted downward, reflecting an anticipated steep decline due to seasonal factors and Medicare-related issues, exacerbated by reduced funding from non-profit foundations that support co-pays for Medicare patients. Despite reporting total revenue of $190.6 million in the preceding quarter, which exceeded expectations, ongoing access challenges and pricing headwinds raise concerns about the sustainability of revenue growth moving forward.

ANI Pharma (ANIP) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 13 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.